148 related articles for article (PubMed ID: 7531876)
1. A pilot study of pro-urokinase in the treatment of deep vein thrombosis.
Moia M; Mannucci PM; Pini M; Prandoni P; Gurewich V
Thromb Haemost; 1994 Sep; 72(3):430-3. PubMed ID: 7531876
[TBL] [Abstract][Full Text] [Related]
2. Studies on the medical treatment of deep vein thrombosis.
Schulman S
Acta Med Scand Suppl; 1985; 704():1-68. PubMed ID: 3913282
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of intravenous prourokinase and a combination of prourokinase and urokinase in acute myocardial infarction.
Bode C; Schoenermark S; Schuler G; Zimmermann R; Schwarz F; Kuebler W
Am J Cardiol; 1988 May; 61(13):971-4. PubMed ID: 2452564
[TBL] [Abstract][Full Text] [Related]
4. Outcome of treatment of deep-vein thrombosis with urokinase: relationship to dosage, duration of therapy, age of the thrombus and laboratory changes.
D'Angelo A; Mannucci PM
Thromb Haemost; 1984 Apr; 51(2):236-9. PubMed ID: 6740556
[TBL] [Abstract][Full Text] [Related]
5. [Fibrinogen-guided thrombolysis with urokinase of a portal and mesenterial venous thrombosis during an acute episode of ulcerative colitis].
Brueck M; Runde T; Rauber K; Kramer W
Dtsch Med Wochenschr; 2006 Jan; 131(3):84-8. PubMed ID: 16418946
[TBL] [Abstract][Full Text] [Related]
6. Coronary thrombolysis with recombinant single-chain urokinase-type plasminogen activator in patients with acute myocardial infarction.
Van de Werf F; Vanhaecke J; de Geest H; Verstraete M; Collen D
Circulation; 1986 Nov; 74(5):1066-70. PubMed ID: 2429783
[TBL] [Abstract][Full Text] [Related]
7. Recombinant pro-urokinase requires heparin for optimal clot lysis and restoration of blood flow in a canine femoral artery thrombosis model.
Burke SE; Lubbers NL; Nelson RA; Henkin J
Thromb Haemost; 1993 Apr; 69(4):375-80. PubMed ID: 8497850
[TBL] [Abstract][Full Text] [Related]
8. Thrombolytic therapy for acute deep venous thrombosis: how much is enough?
Comerota AJ; Katz ML; White JV
Cardiovasc Surg; 1996 Feb; 4(1):101-4. PubMed ID: 8634837
[TBL] [Abstract][Full Text] [Related]
9. Combined effects of urokinase and heparin on PTT values during thrombolytic therapy.
Sheiman RG; Phillips DA
Angiology; 1993 Feb; 44(2):114-22. PubMed ID: 8434804
[TBL] [Abstract][Full Text] [Related]
10. The safety, efficacy, and pharmacoeconomics of low-dose alteplase compared with urokinase for catheter-directed thrombolysis of arterial and venous occlusions.
Sugimoto K; Hofmann LV; Razavi MK; Kee ST; Sze DY; Dake MD; Semba CP
J Vasc Surg; 2003 Mar; 37(3):512-7. PubMed ID: 12618684
[TBL] [Abstract][Full Text] [Related]
11. Comparison of urokinase, alteplase, and reteplase for catheter-directed thrombolysis of deep venous thrombosis.
Grunwald MR; Hofmann LV
J Vasc Interv Radiol; 2004 Apr; 15(4):347-52. PubMed ID: 15064337
[TBL] [Abstract][Full Text] [Related]
12. Systemic fibrinolytic activity and inhibitor levels during treatment of deep vein thrombosis with urokinase and streptokinase.
Theiss W; Asbeck F; Kriessmann A; Trübestein G; Knoch K; de Swart CA; Marbert GA; van de Loo JC
Thromb Haemost; 1983 Oct; 50(3):664-8. PubMed ID: 6196852
[TBL] [Abstract][Full Text] [Related]
13. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--III. Thrombolytic properties of natural and recombinant urokinase in rabbits with experimental jugular vein thrombosis.
Collen D; Stassen JM; Blaber M; Winkler M; Verstraete M
Thromb Haemost; 1984 Aug; 52(1):27-30. PubMed ID: 6541817
[TBL] [Abstract][Full Text] [Related]
14. [Thrombolytic therapy of deep venous thrombosis. Indications, treatment procedures].
Theiss W
Internist (Berl); 1992 Apr; 33(4):225-31. PubMed ID: 1612846
[No Abstract] [Full Text] [Related]
15. Comparison of dose regimens for the administration of recombinant pro-urokinase in a canine thrombosis model.
Burke SE; Lubbers NL; Nelson RA; Henkin J
Thromb Haemost; 1997 May; 77(5):1025-30. PubMed ID: 9184422
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
17. Post-thrombolysis haemostasis changes after rt-PA treatment in acute cerebral infarct. Correlations with cardioembolic aetiology and outcome.
Sun X; Berthiller J; Derex L; Trouillas P; Diallo L; Hanss M
J Neurol Sci; 2015 Feb; 349(1-2):77-83. PubMed ID: 25619569
[TBL] [Abstract][Full Text] [Related]
18. Role of dextran sulfate in urokinase therapy and evaluation of the effects by estimation of plasmin inhibitor, fibrinogenolytic degradation products, and fibrinolytic degradation products.
Hasegawa H; Nagata H; Yamauchi M; Murakoshi T; Oguma Y; Takei H; Seya T; Murao M
Jpn Heart J; 1982 May; 23(3):339-47. PubMed ID: 6178853
[TBL] [Abstract][Full Text] [Related]
19. Fibrinolytic guidelines in diabetes.
Sharma GV; Mukerjee DK; Sasahara AA
Geriatrics; 1982 Apr; 37(4):38-42, 46. PubMed ID: 7060947
[TBL] [Abstract][Full Text] [Related]
20. Thrombolytic treatment of acute thrombotic obstruction with disk valve prostheses: experience with 26 cases.
Roudaut MF; Ledain L; Roudaut R; Besse P; Boisseau MR
Semin Thromb Hemost; 1987 Apr; 13(2):201-5. PubMed ID: 3629262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
